ArticleScientific reports2025
Risk factors and neurodevelopmental outcomes of post-neonatal seizures up to age three in very-low-birthweight infants based on a nationwide cohort.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Growth and Neurodevelopmental Outcomes in Children with Cerebral Palsy: A Nationwide Population-Based Study.Children (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
We assessed the risk factors of post-neonatal anti-epileptic medications after neonatal intensive care unit discharge (PD-AED) and neurodevelopmental (ND) outcomes by age three in very-low-birth-weight infants (VLBWIs), with 7,292 VLBWIs born in 2013-2020 using the Korean Neonatal Network data. We assessed the risk factor of PD-AED and compared the risks for cerebral palsy (CP), blindness, deafness, and ND impairments between five groups: group 1, no seizure; group 2, neonatal seizure only; group 3, neonatal seizure + PD-AED before age three; group 4, neonatal seizure + PD-AED up to age three; group 5, PD-AED without neonatal seizure. By age three, 515 infants (7.1%) had seizures and 241 infants (3.8%) had PD-AED. Higher GA, intra-ventricular hemorrhage ≥ grade 3, post-hemorrhagic hydrocephalus, neonatal seizures, cystic periventricular leukomalacia, necrotizing enterocolitis ≥ stage 2, and moderate to severe bronchopulmonary dysplasia increased the risk of PD-AED. Compared to other groups, group 1 had the lowest risk of CP, while group 4 had the highest. The risk of hearing loss was higher in group 4 compared to groups 1, 2, and 5. Seizures at any time point increased the risk of CP. In infants with neonatal seizures, longer time on anti-epileptic medications also increased the CP risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.